S&P 500   3,678.43 (+2.59%)
DOW   29,490.89 (+2.66%)
QQQ   273.53 (+2.35%)
AAPL   142.45 (+3.08%)
MSFT   240.74 (+3.37%)
META   138.61 (+2.16%)
GOOGL   98.64 (+3.13%)
AMZN   115.88 (+2.55%)
TSLA   242.40 (-8.61%)
NVDA   125.12 (+3.07%)
NIO   15.49 (-1.78%)
BABA   80.45 (+0.58%)
AMD   66.11 (+4.34%)
T   15.90 (+3.65%)
MU   51.72 (+3.23%)
CGC   2.91 (+6.59%)
F   11.47 (+2.41%)
GE   63.60 (+2.73%)
DIS   97.13 (+2.97%)
AMC   6.88 (-1.29%)
PYPL   87.18 (+1.29%)
PFE   44.14 (+0.87%)
NFLX   239.04 (+1.53%)
S&P 500   3,678.43 (+2.59%)
DOW   29,490.89 (+2.66%)
QQQ   273.53 (+2.35%)
AAPL   142.45 (+3.08%)
MSFT   240.74 (+3.37%)
META   138.61 (+2.16%)
GOOGL   98.64 (+3.13%)
AMZN   115.88 (+2.55%)
TSLA   242.40 (-8.61%)
NVDA   125.12 (+3.07%)
NIO   15.49 (-1.78%)
BABA   80.45 (+0.58%)
AMD   66.11 (+4.34%)
T   15.90 (+3.65%)
MU   51.72 (+3.23%)
CGC   2.91 (+6.59%)
F   11.47 (+2.41%)
GE   63.60 (+2.73%)
DIS   97.13 (+2.97%)
AMC   6.88 (-1.29%)
PYPL   87.18 (+1.29%)
PFE   44.14 (+0.87%)
NFLX   239.04 (+1.53%)
S&P 500   3,678.43 (+2.59%)
DOW   29,490.89 (+2.66%)
QQQ   273.53 (+2.35%)
AAPL   142.45 (+3.08%)
MSFT   240.74 (+3.37%)
META   138.61 (+2.16%)
GOOGL   98.64 (+3.13%)
AMZN   115.88 (+2.55%)
TSLA   242.40 (-8.61%)
NVDA   125.12 (+3.07%)
NIO   15.49 (-1.78%)
BABA   80.45 (+0.58%)
AMD   66.11 (+4.34%)
T   15.90 (+3.65%)
MU   51.72 (+3.23%)
CGC   2.91 (+6.59%)
F   11.47 (+2.41%)
GE   63.60 (+2.73%)
DIS   97.13 (+2.97%)
AMC   6.88 (-1.29%)
PYPL   87.18 (+1.29%)
PFE   44.14 (+0.87%)
NFLX   239.04 (+1.53%)
S&P 500   3,678.43 (+2.59%)
DOW   29,490.89 (+2.66%)
QQQ   273.53 (+2.35%)
AAPL   142.45 (+3.08%)
MSFT   240.74 (+3.37%)
META   138.61 (+2.16%)
GOOGL   98.64 (+3.13%)
AMZN   115.88 (+2.55%)
TSLA   242.40 (-8.61%)
NVDA   125.12 (+3.07%)
NIO   15.49 (-1.78%)
BABA   80.45 (+0.58%)
AMD   66.11 (+4.34%)
T   15.90 (+3.65%)
MU   51.72 (+3.23%)
CGC   2.91 (+6.59%)
F   11.47 (+2.41%)
GE   63.60 (+2.73%)
DIS   97.13 (+2.97%)
AMC   6.88 (-1.29%)
PYPL   87.18 (+1.29%)
PFE   44.14 (+0.87%)
NFLX   239.04 (+1.53%)
NASDAQ:HSKA

Heska - HSKA Stock Forecast, Price & News

$73.31
+0.39 (+0.53%)
(As of 10/3/2022 05:11 PM ET)
Add
Compare
Today's Range
$71.42
$75.47
50-Day Range
$72.92
$96.95
52-Week Range
$71.42
$269.03
Volume
114,543 shs
Average Volume
84,291 shs
Market Capitalization
$793.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$184.00

Heska MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
147.9% Upside
$184.00 Price Target
Short Interest
Bearish
11.41% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.89mentions of Heska in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.10) to $0.74 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.83 out of 5 stars

Medical Sector

894th out of 1,093 stocks

Diagnostic Substances Industry

12th out of 17 stocks

HSKA stock logo

About Heska (NASDAQ:HSKA) Stock

Heska Corporation sells veterinary and animal health diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers. It also provides HeskaView Telecytology that provides in-clinic automated microscopic slide scanning and computing equipment; IV infusion pumps; digital radiography hardware and mobile digital radiography products; ultrasound systems; Cloudbank, a Web-based image storage solution; point-of-care products to detect antigens and antibodies associated with infectious and parasitic diseases of animals; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. In addition, the company provides a line of bovine vaccines; biological and pharmaceutical products to other animal health companies; and turnkey services comprising research, licensing, production, labeling, and packaging; and validation support and distribution services. It sells its products to veterinarians through a telephone sales force, and third-party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. The company was founded in 1988 and is based in Loveland, Colorado.

Receive HSKA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Heska and its competitors with MarketBeat's FREE daily newsletter.

HSKA Stock News Headlines

In 20 years, this little-known trader didn’t have a single losing year…
In his debut video, Market Wizard Larry Benedict reveals how to make all the money you need, in any market, using a single stock. Click here to watch the video and get the name and ticker of the one stock that could put you on the road to financial success.
In 20 years, this little-known trader didn’t have a single losing year…
In his debut video, Market Wizard Larry Benedict reveals how to make all the money you need, in any market, using a single stock. Click here to watch the video and get the name and ticker of the one stock that could put you on the road to financial success.
Piper Sandler Raises Heska (NASDAQ:HSKA) Price Target to $170.00
See More Headlines
Receive HSKA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Heska and its competitors with MarketBeat's FREE daily newsletter.

HSKA Company Calendar

Last Earnings
11/04/2021
Today
10/03/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HSKA
Employees
655
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$184.00
High Stock Price Forecast
$250.00
Low Stock Price Forecast
$155.00
Forecasted Upside/Downside
+151.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-1,150,000.00
Pretax Margin
-7.95%

Debt

Sales & Book Value

Annual Sales
$253.74 million
Cash Flow
$1.05 per share
Book Value
$40.69 per share

Miscellaneous

Free Float
9,629,000
Market Cap
$793.14 million
Optionable
Not Optionable
Beta
1.51

Key Executives

  • Mr. Kevin S. WilsonMr. Kevin S. Wilson (Age 50)
    CEO, Pres & Director
    Comp: $1.84M
  • Ms. Catherine I. Grassman CPAMs. Catherine I. Grassman CPA (Age 46)
    Exec. VP & CFO
    Comp: $583.3k
  • Dr. Nancy Wisnewski (Age 59)
    Exec. VP & COO
    Comp: $581.23k
  • Mr. Christopher D. Sveen (Age 39)
    EVP, Chief Admn. Officer, Gen. Counsel, Corp. Sec. & Pres of Diamond Animal Health
    Comp: $536.41k
  • Mr. Steven M. Eyl (Age 56)
    Exec. VP, Chief Commercial Officer & Pres of scil animal care company
    Comp: $587.63k
  • Mr. Jon Aagaard
    Director of Investor Relations
  • Mr. Anthony C. Providenti Jr. (Age 55)
    Exec. VP of Corp. Devel.
  • Ms. Eleanor F. Baker (Age 37)
    Exec. VP, MD & COO of scil animal care company
  • Daniel J. Pollack
    VP of Imaging Operations, Treasurer & Assistant Sec.
  • Laurie E. Peterson
    VP of Heska Des Moines













HSKA Stock - Frequently Asked Questions

Should I buy or sell Heska stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Heska in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" HSKA shares.
View HSKA analyst ratings
or view top-rated stocks.

What is Heska's stock price forecast for 2022?

3 Wall Street analysts have issued 1-year price objectives for Heska's stock. Their HSKA share price forecasts range from $155.00 to $250.00. On average, they anticipate the company's share price to reach $184.00 in the next twelve months. This suggests a possible upside of 152.3% from the stock's current price.
View analysts price targets for HSKA
or view top-rated stocks among Wall Street analysts.

How have HSKA shares performed in 2022?

Heska's stock was trading at $182.49 on January 1st, 2022. Since then, HSKA shares have decreased by 60.0% and is now trading at $72.92.
View the best growth stocks for 2022 here
.

When is Heska's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our HSKA earnings forecast
.

How were Heska's earnings last quarter?

Heska Co. (NASDAQ:HSKA) released its quarterly earnings data on Thursday, November, 4th. The medical research company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of $0.04 by $0.23. The medical research company had revenue of $60.24 million for the quarter, compared to analyst estimates of $63.80 million. Heska had a negative net margin of 6.86% and a negative trailing twelve-month return on equity of 1.21%. The company's revenue for the quarter was up 6.4% on a year-over-year basis. During the same quarter last year, the company posted ($0.25) earnings per share.

What guidance has Heska issued on next quarter's earnings?

Heska issued an update on its FY 2022 earnings guidance on Tuesday, September, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $273.00 million-$277.00 million, compared to the consensus revenue estimate of $283.56 million.

What is Kevin S. Wilson's approval rating as Heska's CEO?

5 employees have rated Heska Chief Executive Officer Kevin S. Wilson on Glassdoor.com. Kevin S. Wilson has an approval rating of 57% among the company's employees. This puts Kevin S. Wilson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Heska own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Heska investors own include Gilead Sciences (GILD), Exxon Mobil (XOM), Netflix (NFLX), Biogen (BIIB), AbbVie (ABBV), Amgen (AMGN), Broadcom (AVGO), Alibaba Group (BABA), Exelixis (EXEL) and Merck & Co., Inc. (MRK).

What is Heska's stock symbol?

Heska trades on the NASDAQ under the ticker symbol "HSKA."

How do I buy shares of Heska?

Shares of HSKA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Heska's stock price today?

One share of HSKA stock can currently be purchased for approximately $72.92.

How much money does Heska make?

Heska (NASDAQ:HSKA) has a market capitalization of $788.92 million and generates $253.74 million in revenue each year. The medical research company earns $-1,150,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis.

How many employees does Heska have?

The company employs 655 workers across the globe.

How can I contact Heska?

Heska's mailing address is 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO, 80538. The official website for the company is www.heska.com. The medical research company can be reached via phone at (970) 493-7272, via email at investorrelations@heska.com, or via fax at 970-619-3003.

This page (NASDAQ:HSKA) was last updated on 10/3/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.